NCT00264953View on ClinicalTrials.gov

HD11 for Intermediate Stages

PHASE3CompletedINTERVENTIONAL

Enrollment

1,395

Participants

Timeline

Start Date

May 31, 1998

Primary Completion Date

January 31, 2003

Conditions

Hodgkin´s Lymphoma

Interventions

DRUG

Adriamycin

DRUG

Bleomycin

DRUG

Vinblastine

DRUG

DTIC

DRUG

Etoposide

DRUG

Procarbazine

DRUG

Prednisone

DRUG

Vincristine

RADIATION

radiation therapy

20 or 30Gy IF-RT

All Listed Sponsors

lead

University of Cologne

OTHER

NCT00264953 - HD11 for Intermediate Stages | Biotech Hunter | Biotech Hunter